

RESEARCH ARTICLE

Lithium Chloride Dependent Glycogen Synthase Kinase 3 Inactivation Links Oxidative DNA Damage, Hypertrophy and Senescence in Human Articular Chondrocytes and Reproduces Chondrocyte Phenotype of Obese Osteoarthritis Patients

Serena Guidotti^{1,2}, Manuela Minguzzi^{1,2}, Daniela Platano^{1,2,3}, Luca Cattini^{1,4}, Giovanni Trisolino⁵, Erminia Mariani^{1,2,4}, Rosa Maria Borzi^{1,4*}

1 Laboratorio di Immunoreumatologia e Rigenerazione Tessutale, Istituto Ortopedico Rizzoli, Bologna, Italy, **2** Dipartimento di Scienze Mediche e Chirurgiche-DIMEC, Università di Bologna, Bologna, Italy, **3** Dipartimento di Scienze Biomediche e Neuromotorie-DIBINEM, Università di Bologna, Bologna, Italy, **4** Dipartimento RIT, Laboratorio RAMSES, Istituto Ortopedico Rizzoli, Bologna, Italy, **5** Chirurgia ricostruttiva articolare dell'anca e del ginocchio, Istituto Ortopedico Rizzoli, Bologna, Italy

These authors contributed equally to this work.

* rosamaria.borzi@ior.it



OPEN ACCESS

Citation: Guidotti S, Minguzzi M, Platano D, Cattini L, Trisolino G, Mariani E, et al. (2015) Lithium Chloride Dependent Glycogen Synthase Kinase 3 Inactivation Links Oxidative DNA Damage, Hypertrophy and Senescence in Human Articular Chondrocytes and Reproduces Chondrocyte Phenotype of Obese Osteoarthritis Patients. PLoS ONE 10(11): e0143865. doi:10.1371/journal.pone.0143865

Editor: Gabriele Saretzki, University of Newcastle, UNITED KINGDOM

Received: July 7, 2015

Accepted: November 9, 2015

Published: November 30, 2015

Copyright: © 2015 Guidotti et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper or in the Supporting Information files.

Funding: This work was supported by RBAP10KCNS (Ministero dell'Istruzione, dell'Università e della Ricerca, <http://www.istruzione.it>) to Erminia Mariani; Fondi Cinque per mille (Ministero della Salute, <http://www.salute.gov.it>) to Laboratorio di Immunoreumatologia e Rigenerazione Tessutale IOR, Bologna. The funders had no role in

Abstract

Introduction

Recent evidence suggests that GSK3 activity is chondroprotective in osteoarthritis (OA), but at the same time, its inactivation has been proposed as an anti-inflammatory therapeutic option. Here we evaluated the extent of GSK3 β inactivation *in vivo* in OA knee cartilage and the molecular events downstream GSK3 β inactivation *in vitro* to assess their contribution to cell senescence and hypertrophy.

Methods

In vivo level of phosphorylated GSK3 β was analyzed in cartilage and oxidative damage was assessed by 8-oxo-deoxyguanosine staining. The *in vitro* effects of GSK3 β inactivation (using either LiCl or SB216763) were evaluated on proliferating primary human chondrocytes by combined confocal microscopy analysis of Mitotracker staining and reactive oxygen species (ROS) production (2',7'-dichlorofluorescein diacetate staining). Downstream effects on DNA damage and senescence were investigated by western blot (γ H2AX, GADD45 β and p21), flow cytometric analysis of cell cycle and light scattering properties, quantitative assessment of senescence associated β galactosidase activity, and PAS staining.

study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Results

In vivo chondrocytes from obese OA patients showed higher levels of phosphorylated GSK3 β , oxidative damage and expression of GADD45 β and p21, in comparison with chondrocytes of nonobese OA patients. LiCl mediated GSK3 β inactivation *in vitro* resulted in increased mitochondrial ROS production, responsible for reduced cell proliferation, S phase transient arrest, and increase in cell senescence, size and granularity. Collectively, western blot data supported the occurrence of a DNA damage response leading to cellular senescence with increase in γ H2AX, GADD45 β and p21. Moreover, LiCl boosted 8-oxo-dG staining, expression of IKK α and MMP-10.

Conclusions

In articular chondrocytes, GSK3 β activity is required for the maintenance of proliferative potential and phenotype. Conversely, GSK3 β inactivation, although preserving chondrocyte survival, results in functional impairment via induction of hypertrophy and senescence. Indeed, GSK3 β inactivation is responsible for ROS production, triggering oxidative stress and DNA damage response.

Introduction

Healthy articular adult chondrocytes live in a maturation arrested state keeping a tight and low turnover of extracellular matrix proteins. Osteoarthritis (OA) is the result of the loss of this maturational arrested state [1] under the effects of a number of different pathogenetic mechanisms.

GSK3, an enzyme with many functions in intracellular signaling and metabolic control of the cell [2] is among the molecular constraints which keep chondrocytes in the “arrested state”. GSK3 belongs to the β -catenin degradation complex and acts by keeping an inactive phosphorylated form of β -catenin thus preventing its nuclear translocation and transcriptional activation of TCF/LEF complex. A tightly regulated level of β -catenin signaling must be guaranteed for an healthy articular cartilage [3]. A fine tuning of GSK3 activity is required for chondrogenesis and skeletal development. Despite functional redundancy for GSK3 α and β in murine chondrocyte differentiation [4], the different phenotypes of global GSK3- α or β knockout indicated a more pivotal role for GSK3 β that is also selectively expressed in articular chondrocytes [5].

Inhibition of GSK3 activity achieved by phosphorylation of serine-21 or serine-9 in isoform α and β , respectively, is a key event in chondrocyte maturation within “temporary cartilage” in skeletal development, under the control of regulatory kinases which drive the process towards hypertrophy and terminal differentiation. An investigation of GSK3 β activity in human OA tissues could help in understanding the relevance of this pathway in the homeostasis of “permanent cartilage” and particularly in correlation with metabolic risk factors. Previous studies have pinpointed that human OA tissues over-express Smurf2 [6] whose conditional over-expression in mice is followed by inhibition and proteasomal degradation of GSK3 β , upregulation of β -catenin and articular cartilage degeneration [7].

Metabolic Syndrome (MetS: overweight, hypertension, dyslipidaemia and impaired glucose tolerance) is a global epidemic, affecting 23% of the general population with more than 2.5 fold prevalence in OA patients [8]. MetS indeed greatly worsen the risk of occurrence and

progression of knee OA [9] and, recently, BMI has been pointed at as a significant predictor of knee OA [10]. MetOA is now recognized as having a peculiar pathogenesis compared to other OA phenotypes [11].

In the present study, we investigated the extent of GSK3 β inactivation in OA knee cartilage explants. We found occurrence of articular chondrocytes with inactive GSK3 β in obese patients thus hinting at GSK3 β as one potential mechanism whereby metabolic factors impact on OA. The effects of GSK3 β inactivation were investigated in vitro using primary human chondrocytes. GSK3 β inactivation (LiCl, SB216763, gene silencing strategies, insulin) consistently showed dramatic effects on proliferation. With regards to the underlying molecular mechanisms, LiCl mediated GSK3 β inactivation increased mitochondrial ROS production that led to oxidative damage (increased 8-oxo-deoxyguanosine), DNA damage response (increased expression of γ H2AX and growth arrest and DNA damage-inducible protein 45 β (GADD45 β)) and cell senescence (transient S phase arrest, increased expression of the senescence marker p21, SA- β galactosidase and PAS staining).

These findings provide a link between metabolic factors and osteoarthritis, via GSK3 β inactivation which promotes at the same time survival, hypertrophy and senescence of articular chondrocytes and question the use of LiCl as a drug for OA treatment.

Materials and Methods

Preclinical research involving human OA patient knee cartilage samples at the Rizzoli Orthopaedic Institute was carried out in compliance with the Helsinki declaration, and subjected to the approval of the ethics committee/institutional review board of the Institute ("Comitato Etico dell'Istituto Ortopedico Rizzoli"), which included documentation of written patient consent forms. After the retrieval of arthroplasty-derived tissues, all patient identifiers were removed and the samples were coded by arbitrary designations to distinguish them solely for experimental purposes.

Cartilage explants

Osteochondral specimen were established from seven patients with detailed characterization of metabolic features [8]. For some patients multiple samples were utilized. 5 out of these 7 patients were obese [body mass index (BMI) over 30]. After removal of most of the subchondral bone, the cartilage cylinders were embedded in OCT, snap frozen and kept at -80°C until processing with immunohistochemistry or immunofluorescence essentially as described in [12]. These cartilage samples were graded 1–2 according to Safranin O staining [13] and with viable cells.

Control experiments were also carried out on four samples derived from disease-free cartilage of patients who had underwent leg amputation for bone tumors.

A first screening was carried out on normal and osteoarthritic cartilage to detect expression and subcellular localization of: phospho-GSK3 β [clone EPR2286Y, Millipore]. Then, since normal cartilage was phospho-GSK3 β negative, only OA samples were analysed to detect expression of 8-hydroxy-2'-deoxyguanosine (8-oxo-dG, clone 2E2, Trevigen), GADD45 β [sc-8776, Santa Cruz Biotechnology (SCBT)], p21 (sc-756, SCBT), senescence associated β -galactosidase (sc-19119, SCBT), in the articular cartilage tissue from superficial to deep zones.

The subcellular localization of phospho-GSK3 β or GADD45 β was evaluated by reference to nuclear counterstaining (Sybr green 1:10,000, Molecular Probes).

To provide a quantitative assessment of the staining pattern, an image analysis was carried out. Two 20x fields for each layer (superficial, intermediate and deep) of the cartilage sections under analysis were examined for each patient. The number of cells was automatically counted

by means of the DAPI nuclear counterstaining (selected to avoid interference with the evaluation of the intensity of the Fast Red substrate, that could arise in the case of colorimetric nuclear counterstaining) and then the cells underwent an automatic analysis procedure exploiting the NIS software (NIKON). A threshold was set in order to take into account only cells above a given staining intensity and to establish the cell percentage above that threshold. These percentages are then reported separately for obese and non obese patients showing the different staining levels for superficial, mid and deep cartilage layers.

Chondrocyte cultures

Primary chondrocytes were obtained from 14 OA patients [12], expanded in culture up to passage 1 (p1) and then used as described below. We chose OA chondrocytes to study the effects of GSK3 β inactivation *in vitro* since LiCl has been recently proposed as a therapeutic option for the treatment of this disease [14].

Time-lapse evaluation of ROS production downstream GSK3 β inactivation. Chondrocytes were plated in Petri dishes with 0.17 mm thin glass well (Cell Culture Dish, World Precision Instruments Germany GmbH), cultured for 72 hours, and then either left unstimulated or treated for 4 hours with 5 or 10 mM LiCl or with 10 μ M SB216763, that behaves as a rather selective inhibitor for GSK3 at that concentration [15]. Mitochondrial involvement was analysed by “time lapse” 30 μ M 2',7'-Dichlorofluorescein diacetate (DCHF-DA) ROS staining overlapping with Mitotracker Orange CMTMRos (a mitochondrial staining, Molecular Probes) along with Hoechst 33258 nuclear counterstaining. Noteworthy, DCHF-DA is still considered one of the most versatile indicators of “generalized cellular oxidative stress” [Molecular Probes’s A guide to fluorescent probes and labeling technologies” 11ty edition (2010)], yielding quantitative imaging results essentially similar to other more recently developed probes [16]. The acquisition of signals of cells in different conditions was taken at comparable stimulus and probe incubation times and with the same instrument settings for excitation and acquisition.

Fluorescent signals were acquired by confocal microscopy as in [12].

Effects of GSK3 β inhibition on cell growth. Chondrocyte cultures from 14 different patients were used to investigate the effect of GSK3 β inhibition on cell growth, cell cycle and senescence. Cells were plated at low density (10,000–15,000 cells per cm²) to rule out biased evaluation of senescence [17].

After 72 hours, cultures were kept either unstimulated or stimulated for 8, 16 and 24 hours with GSK3 β inhibitors: 5 mM LiCl or 10 μ M SB216763 [15] or 33 nM insulin [18]. At the end, cells were recovered for western blot analysis or fixed (10 min at RT with 2% PFA) for Flow Cytometry or detection of senescence associated β -galactosidase (SA- β Gal) activity and PAS staining. The cell number of the samples stimulated with GSK3 β inhibitors was normalized to that of the control to obtain both the “normalized count” (each count referred to that of the control at 8 hours according to the formula: count/countNS8h) as well as the “percentage of decreased count” (each count referred to that of the control at each time, according to the formula: (countGSK3 β inhibitor-countNS)/countNS* 100).

Effects of GSK3 β inhibition on cell cycle, scatter properties and 8-oxo-dG. Flow cytometry was employed to evaluate cell cycle by mean of DNA staining (Sytox green, Molecular Probes, at 5 μ M) of cells previously fixed with 2% PFA, post-fixed with 10 μ l methanol and RNase treated (2.5 U RNase One, Promega plus 100 μ g/ml RNase A, Sigma). Analyses were performed using a FACS Canto II flow cytometer (BD).

Light scattering properties of the cells were analyzed by assessing both the forward scatter (FSC) as a mean to evaluate the cell size and therefore the hypertrophy promoting activity of

LiCl as well as the side scatter (SSC), which correlates with granularity which increases in cell senescence. The median values of several thousands of cells were obtained and separated for each cell cycle phase for both control and LiCl treated cells, and normalized to the median size of control cells in the G1 phase. The extent of oxidative damage was also assessed by staining accumulation of 8-oxo-dG adducts. Samples were compared taking into account the Mean Channel of Fluorescence Intensity (MCFI) increment, i.e. the difference between the median channel of fluorescence intensity of the cells stained for 8-oxo-dG and that of the same cells probed with the negative control (isotype IgG2 control).

Effects of GSK3 β inhibition on cell senescence and hypertrophy. Senescence was tested conventionally by the assessment of SA- β Gal activity [17] (Senescent Cells Staining kit, Sigma) while progressed differentiation and hypertrophy were tested by scoring an increased glycogen content (PAS staining, SIGMA) [19]. Nearly 10,000 cells were cytospun on a glass slide and processed as recommended by the manufacturer. Then, cells were treated with SyBr Green nuclear counterstaining to undergo an automatic analysis procedure exploiting the NIS software. A threshold was set in order to take into account only cells above a given staining intensity and to establish the cell percentage above that threshold. At least four fields (with 40–160 cells each) were counted for each condition.

Real-time polymerase chain reaction. Following treatments, cells from three patients were also dedicated for REAL TIME PCR analysis. RNA was extracted with Trizol (Invitrogen) and processed essentially as described in [20] with values normalized to GAPDH mRNA expression according to the $2^{-\Delta C_t}$ method [21].

Primers were as follows: GAPDH (GenBank:NM_002046, forward 579–598 and reverse 701–683); IKK α /CHUK (GenBank:NM_001278, forward 1803–1826 and reverse 1865–1888); MMP10 (GenBank:NM_002425.2, forward 1278–1298 and reverse 1472–1449).

Immunoblotting. Proteins induced upon DNA damage were evaluated by western blotting, loading protein lysates corresponding to 150,000 cells, essentially as described in [22]. Signals were revealed with ECL Select kit (GE Healthcare), using the CCD camera acquisition system of Image Station 4000 MM and Carestream Molecular Imaging Software 5.0. (Carestream Health, Inc.). Semi-quantitative analysis of bands was performed considering “optical density” values and using QuantityOne software (BioRad). Fold changes were calculated for each time point on control samples put as 1. In search for a correlation between different proteins, fold change-values for all specimens were pulled.

Experiments were designed to kinetically assess the correlated protein expression of phospho-GSK3 β (D85E12, Cell Signaling Technology), total GSK3 β (clone 27C10, Cell Signaling Technology), γ H2AX (07–164, Upstate–Millipore), GADD45 β (sc-8776, SCBT), cyclin-dependent kinase inhibitor p21 (sc-756, SCBT) and caspase 3 (sc-7148, SCBT). IKK α was detected by clone B78-1, BD Pharmingen. Monoclonal anti-GAPDH (clone 6C5, Chemicon–Millipore) or beta-actin (clone AC-74, Sigma) served as loading controls. Experiments were carried out with cells from at least 6 different patients.

Small interfering RNA-mediated gene silencing. The effects of GSK3 β inhibition were also investigated with gene silencing experiments. To this end, primary human chondrocytes in a 12 well plate were transfected with 25 nM total of either ON-TARGET $plus$ GSK3 β SMARTpool reagents (Thermo Scientific Dharmacon,) or ON-TARGET $plus$ Non-targeting Pool, in combination with Lipofectamine ® RNAiMAX Transfection Reagent (Invitrogen). After transfection, the cells were left in culture for 48 hours in order to express silencing. Then, distinct wells for GSK3 β siRNA (siGSK3 β) or control siRNA (siCTL) were left either untreated or treated with 5 mM LiCl or 10 μ M SB216763 for 8, 16 and 24 hours. Each condition was run in duplicate. Silencing was assessed by comparing GSK3 β expression at gene [by real time PCR, using a primer pair suitable to detect expression of both GSK3 β transcripts (transcript

1: GenBank: NM_002093.3 and transcript 2: GenBank: NM_001146156.1): forward 1699–1719 and reverse 1828–1808]; or protein level (by Flow cytometric analysis of GSK3 β expression calculated as described above, using clone 27C10, Cell Signaling).

Statistics. All data are presented as mean \pm standard error of the mean (SEM), analyzed and graphed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego California USA, www.graphpad.com)

Correlation was tested by Spearman r. Comparison of groups for a categorical variable was assessed by mean of contingency table and Fisher's exact test.

Means of groups were compared with paired Student's t test and considered significant when $P < 0.05$, with * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$. Two tailed Student's t test was used throughout.

Results

Inactivation of GSK3 β in cartilage from OA patients

Our first aim was to carry out a preliminary investigation of the extent of GSK3 β inactivation in OA cartilage samples and to point at any clinical parameters that could affect this marker.

The extent of phospho-GSK3 β was investigated by confocal microscopy and immunohistochemistry onto a set of 15 different knee OA cartilage samples (from 7 patients; in case of replicate samples for the same patients the mean values were considered) and on samples from 4 normal subjects. Normal cartilage was negative to phospho-GSK3 β staining among all layers, while OA cartilage had most phospho-GSK3 β positive cells localized in mid-deep layers with an high (>30%) prevalence of positive cells in obese patients (BMI over 30) ([Fig 1A and 1B](#) and [S1 File](#)). The analysis indicated that the percentage of phospho-GSK3 β positive chondrocytes showed a trend towards a positive correlation with BMI (7 patients: Spearman $r = 0.631$, $p = 0.069$, [Fig 1C](#), left graph) and negative with the age of the patients (Spearman $r = -0.739$, $p = 0.066$ [Fig 1C](#), right graph). The data were also analyzed exploiting a contingency table that distinguished "obese" (BMI >30) and "non obese" patients and "phospho-GSK3 β positive" (>30%) and "phospho-GSK3 β negative" patients. The Fisher's exact test was statistically significant (two tailed p value = 0.0476). phospho-GSK3 β staining in chondrocytes had only an extranuclear pattern ([Fig 1B](#)). An high level of staining was also found in calcified cartilage areas, where terminally differentiated chondrocytes survive, suggesting that a similar phenotype had been improperly recapitulated in OA articular cartilage (bottom 10x and 40x detail of the IHC results shown in the lower panels of [Fig 1A](#)).

GSK3 inactivation *in vitro* determines ROS production and oxidative damage

In monolayer cultures at log phase, GSK3 β inactivation with either LiCl or SB216763 determined increased ROS production in activated mitochondria as detected by combining the green DCHF-DA ROS probe with the red Mitotracker Orange CMTMRos mitochondrial probe, that yielded an orange staining ([Fig 2A](#)). Noteworthy, besides the increased DCHF-DA signal, the increased Mitotracker CMTMRos signal is a confirmation that the treatment with both the GSK3 β inhibitors induces ROS production, since Mitotracker signal is increased by these species [16]. Confocal microscopy analysis revealed interesting morphological features: in most chondrocytes the overlapped staining had a perinuclear pattern, ROS also accumulated in the nucleus (see high magnification image in [Fig 2A](#)) and some characteristic nuclear mitotracker stained spots became evident in treated cells (right images in [Fig 2A](#)).






Fig 1. *In vivo* detection of inactive GSK3 β in osteoarthritic articular chondrocytes. **1A**, Upper row (4x, original magnification): pGSK3 β immunohistochemical staining in normal cartilage and in cartilage from representative examples of a non-obese and an obese patient. Lower images (10x and 40x details): pGSK3 β staining in superficial, mid-deep and calcified cartilage zones, in representative samples derived from a non-obese (left) or from an obese patient (right). **1B**, High magnification images of pGSK3 β staining obtained with confocal microscopy of chondrocytes in the superficial (upper row) or mid-deep layers (lower row) of cartilage derived from a non-obese (left column) or from an obese patient (right column). Bar = 10 μ m. Graph: percentage of phospho-GSK3 β positive cells in superficial or mid-deep layers in non obese (NO, white column) or obese patients (O, black columns) as assessed by confocal microscopy. **1C**, Left graph: percentage of phospho-GSK3 β positive chondrocytes in mid-deep layers of knee cartilage, represented as a function of the Body Mass Index of the patients. Right graph: percentage of phospho-GSK3 β positive chondrocytes in mid-deep layers of knee cartilage, represented as a function of the age of the patients.

doi:10.1371/journal.pone.0143865.g001

To assess the effect of increased ROS production, chondrocytes were stained for 8-oxo-dG, a well known oxidative damage marker [23]. At 16 hours, the LiCl treated cells accumulated a significantly higher level of 8-oxo-dG compared to control cells ($p = 0.024$, $n = 5$; [S2 File](#)).

GSK3 inactivation affects cell proliferation with S-phase arrest

LiCl dependent GSK3 β inactivation impacted on cellular proliferation, with significant cell count reduction at 8, 16, 24. [Fig 2B](#) left graph (and [S2 File](#)) shows the cumulative normalized results of experiments performed with cells from different patients. Similar results were obtained using SB216763 ([Fig 2B](#) right graph and [S2 File](#)), with significantly reduced counts at 16 and 24 hours. For both GSK3 β inhibitors, the percentage reduction was maximal at 24 hours, approaching 15% ([Fig 2B](#), lower graphs).

To confirm that GSK3 β activity impacts on cell proliferation experiments were also carried out with GSK3 β siRNA. Silencing efficiency was very high at both mRNA (83% as assessed by real time PCR analysis of GSK3 β expression in siGSK3 β versus siCTL chondrocytes) or protein level (89% as assessed by Flow cytometry detection of GSK3 β). GSK3 β silencing reproduced the effect of pharmacologic GSK3 β inhibition at 8, 16 and 24 hours with regards to reduction in cell proliferation ([Fig 2C](#) and [S2 File](#)) and in the presence of GSK3 β silencing, the effects of LiCl or SB216763 are abolished with regards to proliferation reduction. [Fig 2C](#) right graph (and [S2 File](#)) shows the Population doublings reduction following either 5 mM LiCl or 10 μ M SB216763 stimulation as percentage of each unstimulated control at 8, 16 and 24 hours of both siCTL and siGSK3 β treated cells [24]. Sytox green DNA staining confirmed a significant cell accumulation in S phase at 24 hours, following treatment with LiCl. [Fig 2D](#) shows the cumulative ($n = 9$ different experiments with LiCl and 4 with SB216763, see also [S2 File](#)) distribution of the cells in each cell cycle phase, and a representative case with data for each time point, on the right.

GSK3 inactivation is responsible for chondrocyte senescence and hypertrophy

GSK3 β inactivation induced chondrocyte senescence as assessed by the significant increase of SA- β Gal activity [17] after 5mM LiCl. Noteworthy, the cells with stronger SA- β Gal staining were larger and with a “hypertrophic” phenotype. A quantitative analysis of the increased percentage of senescent/hypertrophic cells was undertaken at 8, 16 and 24 hours and indicated a significant increase already at 8 hours ([Fig 3A](#) and [S3 File](#)). GSK3 β inactivation by either LiCl or SB216763 also led to glycogen accumulation: the number of PAS positive cells was significantly higher at 24 hours for both 5mM LiCl and 10 μ M SB216763 ([Fig 3B](#) and [S3 File](#)). Compared to SB216763, 5mM LiCl was a more effective stimulus for glycogenesis, since treated




Fig 2. *In vitro* pharmacological inhibition of GSK3 β determines ROS production, oxidative damage, stress dependent growth inhibition and activation of an intra-S checkpoint. **2A**, Compared to control (NS), 5 mM LiCl and 10 μ M SB216763 increases ROS production and mitochondria activation at 4 hours treatment. Merged and separated signals of Hoechst 33258 nuclear counterstaining, DCHF-DA and Mitotracker Orange CMTMRos mitochondrial staining. Right: high magnification detail of a LiCl treated cell. Right Graph: at 16 hours, LiCl (black columns) but not SB216763 (grey columns) induced a significant increased ($n = 5$) accumulation of 8-oxo-dG compared to controls (white columns) on the basis of a flow cytometry analysis. **2B**, LiCl (black columns) and SB216763 (grey columns): longitudinal assessment of the effects of GSK3 β inhibition on cell growth versus the control (white columns). Upper graphs: counts normalized versus the 8 hours count; lower graph: percentage count reduction due to either LiCl or SB216763 at each time point. **2C**, longitudinal assessment of the effects of siRNA mediated GSK3 β silencing (squared columns) on cell growth versus the control non targeting siRNA (white columns). Right graph: Population doublings reduction following either 5 mM LiCl or 10 μ M SB216763 stimulation as percentage of each unstimulated control at 8, 16 and 24 hours of both siCTL and siGSK3 β treated cells **2D**, Left: LiCl determines a significant increased (%) percentage of cells in the S phase at 24 hours, as evidenced by DNA staining (Sytox green, $n = 9$ different experiments with LiCl and 4 with SB216763). Right: a representative example with cell cycle analysis of control (left) versus 5mM LiCl (right) treated cells at each time point. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

doi:10.1371/journal.pone.0143865.g002

cells had a significantly higher PAS staining already at 16 hours. Interestingly, at 24 hours LiCl treatment, hypertrophic chondrocytes showed both stronger level of SA- β Gal and of PAS staining. A flow cytometric analysis combining cell cycle information and light scattering properties confirmed that already at 8 hours stimulation at each cell cycle phase, LiCl treatment led to the accumulation of chondrocytes larger than control and richer of intracellular structures that can reflect the light, as evidenced by their increased forward and side scatter [25], respectively (Fig 3C and S3 File). We also obtained a statistically significant higher level of SA- β Gal staining in siGSK3 β compared to siCTL chondrocytes, while in siGSK3 β cells, the addition of either LiCl or SB216763 did not increase further the level of senescence (Fig 3C and S3 File).

GSK3 inactivation results in a DNA damage response and LiCl increases IKK α expression

As expected, LiCl or SB216763 were effective in increasing the extent of phosphorylated GSK3 β . Noteworthy, the treatment also induced a slight increase of total GSK3 β expression, that also appeared to change in non stimulated cells at 16 and 24 hours, reflecting cell cycle progression. We then performed western blot analysis to investigate whether the LiCl induced increased S phase could be dependent on an activated intra S checkpoint following DNA damage [26]. As shown in the representative case in Fig 4A, LiCl leads to a DNA damage response (DDR), with increased expression of γ H2AX, GADD45 β and p21. Fig 4B and S4 File show the cumulative densitometric analysis of the level of these proteins following either 5mM LiCl or 10 μ M SB216763 treatment. γ H2AX level was increased at 8 hours by both LiCl and SB216763 and at 24 hours by LiCl. Moreover, γ H2AX increase was an effective stimulus for the early induction of GADD45 β , significantly increased by SB216763 at 8 hours and by LiCl at 24 hours. GADD45 β dependence on γ H2AX was further confirmed by the strong correlation between the two proteins (Fig 4D, left graph and S4 File). GADD45 β , in turns, led to an increased expression of p21, a marker of senescence [27], significantly induced at 16 hours by both LiCl and SB216763. The effects of GSK3 β inactivation on cell growth prompted us to investigate regulation of IKK α , involved in chondrocyte proliferation [28]. Fig 4B shows the cumulative results of 8 (LiCl) or 4 (SB216763) independent experiments and indicates that LiCl induces a modest, yet significant increase of IKK α protein expression at both 8 and 16 hours. In keeping with these findings, at 16 hours stimulation, 5mM LiCl but not 10 μ M SB216763 significantly increases IKK α mRNA expression (Fig 4C and S4 File), and of its target gene MMP-10 (Fig 4C and S4 File). IKK α was also found to correlate with GADD45 β expression (Fig 4D, right graph and S4 File).




Fig 3. Effects of GSK3 β inhibition on senescence markers and scatter properties. SA- β Galactosidase activity and PAS staining were quantitatively evaluated by image analysis: cells were automatically detected by SyBr Green nuclear counterstaining and the percentage of cells above a given staining intensity threshold was determined. **3A**, SA- β Galactosidase activity. 5mM LiCl increases the percentage of SA- β Gal positive cells already at 8 hours of treatment (n = 6 different experiments with LiCl and 4 with SB216763). Right images: representative pictures of non stimulated (NS) and LiCl or SB216763 treated cells (10x original magnification). Hypertrophic cells also show the strongest level of SA- β Gal activity. **3B**, PAS staining. A significant increase in PAS staining was observed in chondrocytes treated with 5mM LiCl (n = 5) or 10 μ M SB216763 (n = 4) at 24 hours. Right image: representative pictures showing that hypertrophic cells also has the strongest level of PAS staining (10x original magnification). **3C**, SA- β Galactosidase activity is increased by GSK3 β silencing after 24 hours. **3D**, Cell cycle phase distribution of Forward Scatter (left graph, a parameter related to cell size) and Side scatter (right graph, a parameter related to cell granularity) of different experiments (n = 8 with LiCl and 4 with SB216763), with values normalized to that of each control G1 phase cells. 5mM LiCl treatment determines an increase of scatter values at G1, S and G2M phase. *P < 0.05; **P < 0.01; ***P < 0.001.

doi:10.1371/journal.pone.0143865.g003

Evidence of a DNA damage response associated with GSK3 inactivation in cartilage

In mid-deep layers of cartilage samples derived from obese OA patients, we found occurrence and stronger staining of the axis “oxidative DNA damage>GADD45 β >p21”, responsible for both senescence and hypertrophy after GSK3 β inactivation *in vitro*.

Oxidative DNA damage was investigated by mean of 8-oxo-dG staining [23]. Overall, in cartilage of obese patients we found association of higher staining of phospho-GSK3 β (as detailed in Fig 1), 8-oxo-dG, GADD45 β (with an exclusive cytoplasmic distribution, see inset in Fig 5) and of its target gene p21, and of immunologically detectable SA- β Gal (See Fig 5, lower right panel), suggesting that also in the tissue there is evidence of a mechanistic link between GSK3 β inactivation, DNA damage response and chondrocyte senescence. Fig 5 shows correlated immunohistochemistry experiments on cartilage sections derived from two representative OA cartilage samples resulted negative (upper panel) or positive (lower panel,) for phospho-GSK3 β . Bottom graphs show the image analysis of the percentage of positive cells for the different markers in the different superficial, intermediate and deep cartilage zones in samples derived from non obese and obese patients (S5 File). Obese patients presented significantly higher level of 8-oxo-dG, GADD45 β and p21 in deep cartilage layers.

Insulin mimicks lithium effects on chondrocyte cultures

Given the significant association between the BMI and the percentage of phospho-GSK3 β chondrocytes, we investigated on the factors that can be responsible for the GSK3 β inactivation *in vivo*. Insulin is a likely candidate, known to be frequently increased in obese patients because of insulin resistance. Insulin shares with LiCl the ability to inactivate GSK3 β through the PI3K/Akt pathway [29, 30] although LiCl is able to inactivate GSK3 β through multiple mechanisms [30]. Therefore, we studied the effects of 33 nM insulin [18] on chondrocyte proliferation. Similarly to 5mM LiCl, insulin led to decreased chondrocyte proliferation at 8, 16 and 24 hours (S3 File).

Discussion

The hypothesis of our work is that GSK3 β inactivation can sustain chronic impairment of articular chondrocytes, via a mitochondrial mechanisms [31] that leads to ROS production and cellular senescence.

DNA damage has been found in osteoarthritic samples, in conjunction with a progressive/stress-induced senescence [32]. This condition is worsened by the association of a metabolic syndrome, since obesity is accompanied by a systemic DNA damage response which sustains chronic inflammation [33, 34] and degeneration of multiple post-mitotic tissues. We indeed found the extent of GSK3 β inactivation in OA cartilage correlated with BMI, recently recognized together with age as one of the potential predictor factors for knee osteoarthritis [10].




Fig 4. LiCl treatment determines a DNA damage response and increases expression of markers of chondrocyte differentiation. **4A**, LiCl mediated increased GSK3 β phosphorylation leads to a DNA damage response (DDR) (a representative example of one out of several experiments). The DDR includes markers of DNA damage (double strand breaks evidenced as γ H2AX), increased expression of GADD45 β and p21. **4B**, Cumulative densitometric analysis following either 5mM LiCl (LiCl) or 10 μ M SB216763 (SB) treatment ("n" of experiments detailed within brackets for LiCl and SB216763) of the "fold change increase" in comparison of not stimulated samples (NS) of γ H2AX (7 patients for LiCl and 5 for SB216763), GADD45 β (6,2), p21 (7,3). IKK α (8,4) was also evaluated. **4C**, 16 hours LiCl treatment significantly increased gene expression of IKK α (n = 3) and of its target gene MMP-10 (n = 3). **4D**, Cumulative correlation analysis of the fold changes protein expression values, considering all the samples independently of time and stimulus, indicated the strong association between the hypertrophy marker GADD45 β and both γ H2AX (left graph: Spearman r value = 0.48, p = 0.0066, n = 25) and IKK α (right graph: Spearman r value = 0.37, p = 0.024, n = 30). *P < 0.05; **P < 0.01; ***P < 0.001.

doi:10.1371/journal.pone.0143865.g004

One of the critical criteria for metabolic syndrome is insulin resistance [8]. In this case fat and muscle cells are unable to respond to insulin that increases as a compensatory mechanism and mediates adverse effects in different tissues including cartilage. With regards to signal transduction, it is worth noticing that insulin is able to activate the PI3K/-Akt pathway which then inactivates GSK3 β .

To tease out the consequences of GSK3 β inactivation in chondrocytes, we performed several in vitro experiments with both the pharmacological inhibitor LiCl and the specific inhibitor SB216763. The latter indeed had been tested against a panel of 25 different serine/threonine and tyrosine protein kinases that showed little or no inhibition [15].

The two substances were used at concentrations close to those found to exert similar effects on glucose incorporation, stimulation of glycogen synthase activity and transcription of β -catenin-LEF/TCF regulated reporter gene [15].

Since LiCl is able to activate the PI3K/-Akt pathway and to inhibit GSK3 β [30, 35], it can be considered as a mimicker of insulin or other growth factors or inflammatory cytokines that lead to GSK3 β inactivation as a result of PKC/PI3K/Akt activation [36, 37], whereas the comparison with SB216763 and GSK3 β silencing strategies can help in distinguishing the effects which are uniquely dependent on GSK3 β inactivation versus those which are instead dependent on other signaling molecules.

We used log phase chondrocyte cultures to investigate the effects of GSK3 β inactivation on chondrocyte proliferation, reported to occur in osteoarthritic cartilage as an attempt to keep tissue homeostasis [38]. We found that GSK3 β inactivation is responsible for chondrocyte senescence as detected by impaired proliferation or accumulation of SA- β Gal [39]. We then moved to investigate the molecular mechanisms and found that LiCl or SB216763 dependent GSK3 β inactivation in mitochondria is responsible for sustained ROS production as previously described [31]. Interestingly, we observed occurrence of mitochondrial-nuclear translocation of proteins selectively stained by Mitotracker. It has been reported that during the stress response heat shock proteins functioning as chaperones migrate to the nucleus bound to anti-apoptotic proteins [40]. Therefore, GSK3 β inhibition activates compensatory activities of the cells to protect themselves from oxidative stress.

Intracellular ROS generation then damages DNA and triggers a DNA damage response, known to be involved in senescence induction and maintenance [26].

GSK3 inhibition indeed increased γ H2AX, the marker of double strand breaks, corresponding to the phosphorylated form of the histone H2AX, that tags double strand breaks in DNA, to organize the multimeric protein complex for DNA repair. The DNA damage determines induction of GADD45 β , a growth arrest and DNA damage inducible gene that plays an important role in chondrocyte terminal differentiation [41] and reported to drive chondrocyte hypertrophy and prevent apoptosis of hypertrophic chondrocytes [42]. GADD45 β could participate




Fig 5. Association of oxidative damage, markers of DDR and senescence in mid-deep layers of cartilage of obese patients. 8-oxo-dG, GADD45β, p21 and SA-β-Gal assessed with immunohistochemistry and colorimetric detection and bright field images at 4x original magnification: cases representative of non obese (upper panel) or obese (lower panel) patients. High magnification inset shows the prevalent cytoplasmic localization of GADD45β signal (red staining) with sybr green as a nuclear counterstaining. For each marker, experiments were carried out in the same experimental session to rule out biases in comparing the signal intensity. Below the pictures for each marker a cumulative assessment (with mean and standard error of mean) of the percentage of positive cells in superficial, intermediate and deep layers in non obese (NO, white column) or obese patients (O, black columns) is shown. *P < 0.05; **P < 0.01;***P < 0.001.

doi:10.1371/journal.pone.0143865.g005

in cell cycle arrest being responsible for both an intra S checkpoint [43], such as that observed in our LiCl treated cultures and induction of p21 [27], the cyclin dependent kinase inhibitor (CKI) induced following DNA damage [26] and involved in cell cycle arrest and DNA repair.

DNA damage was also assessed considering 8-oxo-dG staining, one of the best characterized marker of nuclear and mitochondrial oxidative stress [23]. Noteworthy, mitochondrial DNA is much more susceptible than nuclear DNA to oxidative damage because of enhanced ROS formation and reduced repair capacity [44]. We easily detected increased γH2AX following GSK3β inhibition, but 8-oxo-dG increased only after LiCl and not SB216763. SA-β Gal [17] and PAS staining [19] were then used not alone, but in combination to tease out the differential effects downstream GSK3β inhibition. Investigation of both aspects allowed us to distinguish

the effects on either true senescence or hypertrophy. Noteworthy, only LiCl and not SB216763 led to increased cell expression of SA- β Gal. However, GSK3 β inactivation by means of silencing strategies was effective in producing a significant increase of cell senescence, possibly because of the greater magnitude of the effect compared to SB216763. At the same time cell scatter properties indicated increased cell size and granularity in cells treated with LiCl. On the other hand, as expected due to the effect on glycogen synthase [15], both LiCl and SB216763 increased the percentage of PAS positive cells. Enhanced glycogenesis has been linked to cellular senescence and aging [19] and also proposed as a marker of hypertrophic chondrocytes [45]. Overall, the above findings suggest that induction of senescence may require a critical level of ROS generation that in our experimental setting has only been achieved by LiCl. Indeed, LiCl is able to induce ROS not only because of GSK3 β inhibition [31] but also because of additional signaling mechanisms such as the activation of PI3K/Akt [30, 46], as downstream the action of insulin [29] or growth factors that drive chondrocyte differentiation. It is worthy to underline that the PI3K/Akt pathway has been recently connected with the activation of the NADPH oxidase family of enzymes [46].

Therefore, following LiCl treatment, senescence and hypertrophy overlap in chondrocytes. In keeping with this concept, a link between senescence and articular chondrocyte terminal differentiation has already been reported [47]. Indeed, chondrocyte stimulation with LiCl is known to be associated with accumulation and transcriptional activity of β -catenin which causes progression from the healthy articular toward a more terminally differentiated phenotype [48].

Recently, LiCl has been suggested to protect against cartilage degradation in osteoarthritis [14, 49]. Our findings instead show that LiCl could have deleterious effects on cartilage homeostasis. Indeed, despite its inhibiting activity on NF- κ B [14] or p38 MAPK [49] pathways, LiCl promotes not only chondrocyte hypertrophy but also senescence and increased gene/protein expression of IKK α and increased gene expression of its target MMP-10, pivotal in ECM remodelling and chondrocyte terminal differentiation in both human and murine chondrocytes.

A similar association of phospho-GSK3 β >oxidative stress>GADD45 β >p21 was found in cartilage of obese patients whose mid-deep layers presented markedly increased levels of 8-oxo-dG rather than γ H2AX that represents a transient phenomenon [50, 51].

Chondrocyte susceptibility to oxidative damage is well known as well as implication for ROS in intrinsic senescence of OA tissues. Oxidative stress is in turn the major determinant underlying the “extrinsic” or stress-induced senescence of aging chondrocytes [52, 53] and according to the findings of the present paper, of chondrocytes in cartilage of obese OA patients.

We recently reported that progressed differentiation, increased extracellular matrix remodeling and senescence can coincide in chondrocytes exposed to chronic inflammatory stimuli which are responsible for enhanced expression of p16, one of the two CKI involved in senescence dependent cell cycle arrest [47]. In this paper we instead show that following GSK3 β inactivation, increased intracellular ROS trigger a DNA damage response which leads to an up-regulated expression of p21, the other CKI. It is noteworthy that the “postmitotic” status of healthy articular chondrocytes features an “housekeeping” expression level of the two CKIs, which may change in OA. p16 is increased in OA chondrocytes compared to aged-matched cells [54]. With regards to p21, conflicting data have been reported in literature. p21 has been found to increase as a function of senescence in SAMP mice as a result of increased GADD45 β expression [27]. The up-regulated p21 expression has been mechanistically correlated to the increased caveolin expression found in both human and rat OA cartilage [55]. Conversely, Rose found decreased p21 in late OA samples, possibly because these were severely degenerated

OA tissues [32]. In the present paper we collected several evidences that *in vitro* LiCl mediated GSK3 inactivation leads to chondrocyte hypertrophy in conjunction with cell senescence as indicated by increased p21 expression. Our findings are in keeping with a previous report which pointed at an association between increased p21 expression and increased chondrocyte hypertrophy in both growth plate and articular cartilage [56]. We also found a high p21 expression in cartilage of obese patients that also present high cell senescence as shown by SA- β gal staining.

Conclusions

In summary, we provide several evidences that GSK3 β activity can be compromised *in vivo* in cartilage of obese OA patients and our *in vitro* experiments indicate that it is instead required for chondrocyte mitochondrial function, tissue homeostasis and prevention of oxidative damage, hypertrophy and senescence. Therefore our findings question the use of LiCl in OA treatment.

Supporting Information

S1 File. Data used in Fig 1.

(XLSX)

S2 File. Data used in Fig 2.

(XLSX)

S3 File. Data used in Fig 3.

(XLSX)

S4 File. Data used in Fig 4.

(XLSX)

S5 File. Data used in Fig 5.

(XLSX)

Acknowledgments

We dedicate this paper to the memory of Andrea Facchini who passed away one year ago. He established the Laboratorio di Immunoreumatologia e Rigenerazione Tissutale (Istituto Ortopedico Rizzoli, Bologna, Italy), grew and directed it for many years and participated to most of the work presented here. This work was supported by FIRB (Ministero dell'istruzione, dell'Università e della Ricerca, Italy) grant RBAP10KCNS and Fondi cinque per mille (Ministero della Salute, Italy).

Author Contributions

Conceived and designed the experiments: SG MM DP RMB. Performed the experiments: SG MM DP LC. Analyzed the data: SG MM DP LC GT RMB. Contributed reagents/materials/analysis tools: GT LC EM. Wrote the paper: SG MM DP GT EM RMB.

References

1. van der Kraan PM, van den Berg WB. Osteoarthritis in the context of ageing and evolution. Loss of chondrocyte differentiation block during ageing. *Ageing Res Rev.* 2008; 7(2):106–13. PMID: [18054526](#).
2. Cohen P, Frame S. The renaissance of GSK3. *Nat Rev Mol Cell Biol.* 2001; 2(10):769–76. Epub 2001/10/05. doi: [10.1038/35096075](#) 35096075 [pii]. PMID: [11584304](#).

3. Lories RJ, Corr M, Lane NE. To Wnt or not to Wnt: the bone and joint health dilemma. *Nat Rev Rheumatol*. 2013; 9(6):328–39. Epub 2013/03/06. doi: [10.1038/nrrheum.2013.25](https://doi.org/10.1038/nrrheum.2013.25) nrrheum.2013.25 [pii]. PMID: [23459013](https://pubmed.ncbi.nlm.nih.gov/23459013/).
4. Itoh S, Saito T, Hirata M, Ushita M, Ikeda T, Woodgett JR, et al. GSK-3alpha and GSK-3beta proteins are involved in early stages of chondrocyte differentiation with functional redundancy through RelA protein phosphorylation. *J Biol Chem*. 2012; 287(35):29227–36. Epub 2012/07/05. doi: [10.1074/jbc.M112.372086](https://doi.org/10.1074/jbc.M112.372086) M112.372086 [pii]. PMID: [22761446](https://pubmed.ncbi.nlm.nih.gov/22761446/); PubMed Central PMCID: [PMC3436165](https://pubmed.ncbi.nlm.nih.gov/PMC3436165/).
5. Gillespie JR, Ulici V, Dupuis H, Higgs A, Dimattia A, Patel S, et al. Deletion of glycogen synthase kinase-3beta in cartilage results in up-regulation of glycogen synthase kinase-3alpha protein expression. *Endocrinology*. 2011; 152(5):1755–66. Epub 2011/02/18. doi: [10.1210/en.2010-1412](https://doi.org/10.1210/en.2010-1412) en.2010-1412 [pii]. PMID: [21325041](https://pubmed.ncbi.nlm.nih.gov/21325041/).
6. Wu Q, Kim KO, Sampson ER, Chen D, Awad H, O'Brien T, et al. Induction of an osteoarthritis-like phenotype and degradation of phosphorylated Smad3 by Smurf2 in transgenic mice. *Arthritis and Rheumatism*. 2008; 58(10):3132–44. Epub 2008/09/30. doi: [10.1002/art.23946](https://doi.org/10.1002/art.23946) PMID: [18821706](https://pubmed.ncbi.nlm.nih.gov/18821706/); PubMed Central PMCID: [PMC2636703](https://pubmed.ncbi.nlm.nih.gov/PMC2636703/).
7. Wu Q, Huang JH, Sampson ER, Kim KO, Zuscik MJ, O'Keefe RJ, et al. Smurf2 induces degradation of GSK-3beta and upregulates beta-catenin in chondrocytes: a potential mechanism for Smurf2-induced degeneration of articular cartilage. *Exp Cell Res*. 2009; 315(14):2386–98. Epub 2009/06/02. doi: [10.1016/j.yexcr.2009.05.019](https://doi.org/10.1016/j.yexcr.2009.05.019) PMID: [19481076](https://pubmed.ncbi.nlm.nih.gov/19481076/); PubMed Central PMCID: [PMC2720571](https://pubmed.ncbi.nlm.nih.gov/PMC2720571/).
8. Zhuo Q, Yang W, Chen J, Wang Y. Metabolic syndrome meets osteoarthritis. *Nat Rev Rheumatol*. 2012; 8(12):729–37. Epub 2012/08/22. doi: [10.1038/nrrheum.2012.135](https://doi.org/10.1038/nrrheum.2012.135) nrrheum.2012.135 [pii]. PMID: [22907293](https://pubmed.ncbi.nlm.nih.gov/22907293/).
9. Yoshimura N, Muraki S, Oka H, Tanaka S, Kawaguchi H, Nakamura K, et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. *Osteoarthritis Cartilage*. 2012; 20(11):1217–26. Epub 2012/07/17. doi: [10.1016/j.joca.2012.06.006](https://doi.org/10.1016/j.joca.2012.06.006) S1063-4584(12)00861-8 [pii]. PMID: [22796312](https://pubmed.ncbi.nlm.nih.gov/22796312/).
10. Blumenfeld O, Williams FM, Hart DJ, Spector TD, Arden N, Livshits G. Association between cartilage and bone biomarkers and incidence of radiographic knee osteoarthritis (RKO) in UK females: a prospective study. *Osteoarthritis Cartilage*. 2013; 21(7):923–9. Epub 2013/04/20. doi: [10.1016/j.joca.2013.04.009](https://doi.org/10.1016/j.joca.2013.04.009) S1063-4584(13)00769-3 [pii]. PMID: [23598177](https://pubmed.ncbi.nlm.nih.gov/23598177/).
11. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. *Lancet*. 2011; 377(9783):2115–26. Epub 2011/06/21. doi: [10.1016/S0140-6736\(11\)60243-2](https://doi.org/10.1016/S0140-6736(11)60243-2) S0140-6736(11)60243-2 [pii]. PMID: [21684382](https://pubmed.ncbi.nlm.nih.gov/21684382/).
12. Borzi RM, Olivetto E, Pagani S, Vitelozzi R, Neri S, Battistelli M, et al. Matrix metalloproteinase 13 loss associated with impaired extracellular matrix remodeling disrupts chondrocyte differentiation by concerted effects on multiple regulatory factors. *Arthritis Rheum*. 2010; 62(8):2370–81. Epub 2010/05/28. doi: [10.1002/art.27512](https://doi.org/10.1002/art.27512) PMID: [20506238](https://pubmed.ncbi.nlm.nih.gov/20506238/); PubMed Central PMCID: [PMC2921033](https://pubmed.ncbi.nlm.nih.gov/PMC2921033/).
13. Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, et al. Osteoarthritis cartilage histopathology: grading and staging. *Osteoarthritis Cartilage*. 2006; 14(1):13–29. Epub 2005/10/26. doi: [10.1016/j.joca.2005.07.014](https://doi.org/10.1016/j.joca.2005.07.014) PMID: [16242352](https://pubmed.ncbi.nlm.nih.gov/16242352/).
14. Minashima T, Zhang Y, Lee Y, Kirsch T. Lithium protects against cartilage degradation in osteoarthritis. *Arthritis Rheumatol*. 2014. Epub 2014/01/29. doi: [10.1002/art.38373](https://doi.org/10.1002/art.38373) PMID: [24470226](https://pubmed.ncbi.nlm.nih.gov/24470226/).
15. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. *Chem Biol*. 2000; 7(10):793–803. Epub 2000/10/18. doi: [10.1074-s1074-5521\(00\)00025-9](https://doi.org/10.1074-s1074-5521(00)00025-9) [pii]. PMID: [11033082](https://pubmed.ncbi.nlm.nih.gov/11033082/).
16. Kuznetsov AV, Kehrer I, Kozlov AV, Haller M, Redl H, Hermann M, et al. Mitochondrial ROS production under cellular stress: comparison of different detection methods. *Anal Bioanal Chem*. 2011; 400(8):2383–90. Epub 2011/02/22. doi: [10.1007/s00216-011-4764-2](https://doi.org/10.1007/s00216-011-4764-2) PMID: [21336935](https://pubmed.ncbi.nlm.nih.gov/21336935/).
17. Severino J, Allen RG, Balin S, Balin A, Cristofalo VJ. Is beta-galactosidase staining a marker of senescence in vitro and in vivo? *Exp Cell Res*. 2000; 257(1):162–71. Epub 2000/06/15. doi: [10.1006/excr.2000.4875](https://doi.org/10.1006/excr.2000.4875) PMID: [10854064](https://pubmed.ncbi.nlm.nih.gov/10854064/).
18. Nikoulina SE, Ciaraldi TP, Mudaliar S, Carter L, Johnson K, Henry RR. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. *Diabetes*. 2002; 51(7):2190–8. Epub 2002/06/28. PMID: [12086949](https://pubmed.ncbi.nlm.nih.gov/12086949/).
19. Seo YH, Jung HJ, Shin HT, Kim YM, Yim H, Chung HY, et al. Enhanced glycogenesis is involved in cellular senescence via GSK3/GS modulation. *Aging Cell*. 2008; 7(6):894–907. Epub 2008/09/11. doi: [10.1111/j.1474-9726.2008.00436.x](https://doi.org/10.1111/j.1474-9726.2008.00436.x) ACE436 [pii]. PMID: [18782348](https://pubmed.ncbi.nlm.nih.gov/18782348/).

20. Manferdini C, Maumus M, Gabusi E, Piacentini A, Filardo G, Peyrafitte JA, et al. Adipose-derived mesenchymal stem cells exert antiinflammatory effects on chondrocytes and synoviocytes from osteoarthritis patients through prostaglandin E2. *Arthritis Rheum*. 2013; 65(5):1271–81. Epub 2013/04/25. doi: [10.1002/art.37908](https://doi.org/10.1002/art.37908) PMID: [23613363](https://pubmed.ncbi.nlm.nih.gov/23613363/).
21. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc*. 2008; 3(6):1101–8. Epub 2008/06/13. PMID: [18546601](https://pubmed.ncbi.nlm.nih.gov/18546601/).
22. Guidotti S, Facchini A, Platano D, Olivotto E, Minguzzi M, Trisolino G, et al. Enhanced osteoblastogenesis of adipose-derived stem cells on spermine delivery via beta-catenin activation. *Stem Cells Dev*. 2013; 22(10):1588–601. Epub 2013/01/11. doi: [10.1089/scd.2012.0399](https://doi.org/10.1089/scd.2012.0399) PMID: [23301872](https://pubmed.ncbi.nlm.nih.gov/23301872/).
23. Markkanen E, Hubscher U, van Loon B. Regulation of oxidative DNA damage repair: the adenine:8-oxo-guanine problem. *Cell Cycle*. 2012; 11(6):1070–5. Epub 2012/03/01. doi: [10.4161/cc.11.6.19448](https://doi.org/10.4161/cc.11.6.19448) PMID: [22370481](https://pubmed.ncbi.nlm.nih.gov/22370481/).
24. Greenwood SK, Hill RB, Sun JT, Armstrong MJ, Johnson TE, Gara JP, et al. Population doubling: a simple and more accurate estimation of cell growth suppression in the in vitro assay for chromosomal aberrations that reduces irrelevant positive results. *Environ Mol Mutagen*. 2004; 43(1):36–44. Epub 2004/01/27. doi: [10.1002/em.10207](https://doi.org/10.1002/em.10207) PMID: [14743344](https://pubmed.ncbi.nlm.nih.gov/14743344/).
25. Takacs-Buia L, Iordachel C, Efimov N, Caloianu M, Montreuil J, Bratosin D. Pathogenesis of osteoarthritis: chondrocyte replicative senescence or apoptosis? *Cytometry B Clin Cytom*. 2008; 74(6):356–62. Epub 2008/05/16. doi: [10.1002/cyto.b.20428](https://doi.org/10.1002/cyto.b.20428) PMID: [18481296](https://pubmed.ncbi.nlm.nih.gov/18481296/).
26. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. *Nat Rev Cancer*. 2008; 8(7):512–22. Epub 2008/06/25. doi: [10.1038/nrc2440](https://doi.org/10.1038/nrc2440) PMID: [18574463](https://pubmed.ncbi.nlm.nih.gov/18574463/).
27. Shimada H, Sakakima H, Tsuchimochi K, Matsuda F, Komiya S, Goldring MB, et al. Senescence of chondrocytes in aging articular cartilage: GADD45 beta mediates p21 expression in association with C/EBP beta in senescence-accelerated mice. *Pathology Research and Practice*. 2011; 207(4):225–31. doi: [10.1016/j.prp.2011.01.007](https://doi.org/10.1016/j.prp.2011.01.007) PMID: [21400004](https://pubmed.ncbi.nlm.nih.gov/21400004/).
28. Olivotto E, Borzi RM, Vitelozzi R, Pagani S, Facchini A, Battistelli M, et al. Differential requirements for IKKalpha and IKKbeta in the differentiation of primary human osteoarthritic chondrocytes. *Arthritis Rheum*. 2008; 58(1):227–39. PMID: [18163512](https://pubmed.ncbi.nlm.nih.gov/18163512/). doi: [10.1002/art.23211](https://doi.org/10.1002/art.23211)
29. Hojlund K. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance. *Dan Med J*. 2014; 61(7):B4890. Epub 2014/08/16. doi: [1600046214168900](https://doi.org/10.1177/1600046214168900) PMID: [25123125](https://pubmed.ncbi.nlm.nih.gov/25123125/).
30. Chiu CT, Chuang DM. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. *Pharmacol Ther*. 2010; 128(2):281–304. Epub 2010/08/14. doi: [10.1016/j.pharmthera.2010.07.006](https://doi.org/10.1016/j.pharmthera.2010.07.006) PMID: [20705090](https://pubmed.ncbi.nlm.nih.gov/20705090/); PubMed Central PMCID: [PMC3167234](https://pubmed.ncbi.nlm.nih.gov/PMC3167234/).
31. Byun HO, Jung HJ, Seo YH, Lee YK, Hwang SC, Seong Hwang E, et al. GSK3 inactivation is involved in mitochondrial complex IV defect in transforming growth factor (TGF) beta1-induced senescence. *Exp Cell Res*. 2012. Epub 2012/06/02. doi: [10.1016/j.yexcr.2012.04.012](https://doi.org/10.1016/j.yexcr.2012.04.012) PMID: [22652454](https://pubmed.ncbi.nlm.nih.gov/22652454/).
32. Rose J, Soder S, Skhirtladze C, Schmitz N, Gebhard PM, Sesselmann S, et al. DNA damage, disordinated gene expression and cellular senescence in osteoarthritic chondrocytes. *Osteoarthritis Cartilage*. 2012; 20(9):1020–8. Epub 2012/06/05. doi: [10.1016/j.joca.2012.05.009](https://doi.org/10.1016/j.joca.2012.05.009) PMID: [22659602](https://pubmed.ncbi.nlm.nih.gov/22659602/).
33. Redon CE, Nakamura AJ, Martin OA, Parekh PR, Weyemi US, Bonner WM. Recent developments in the use of gamma-H2AX as a quantitative DNA double-strand break biomarker. *Aging (Albany NY)*. 2011; 3(2):168–74. Epub 2011/02/18. doi: [10.18632/aging.100284](https://doi.org/10.18632/aging.100284) PMID: [21325706](https://pubmed.ncbi.nlm.nih.gov/21325706/); PubMed Central PMCID: [PMC3082012](https://pubmed.ncbi.nlm.nih.gov/PMC3082012/).
34. Bonet ML, Granados N, Palou A. Molecular players at the intersection of obesity and osteoarthritis. *Curr Drug Targets*. 2011; 12(14):2103–28. Epub 2011/10/26. doi: [15682651110000352](https://doi.org/10.2174/15682651110000352) PMID: [22023406](https://pubmed.ncbi.nlm.nih.gov/22023406/).
35. Liu KJ, Lee YL, Yang YY, Shih NY, Ho CC, Wu YC, et al. Modulation of the development of human monocyte-derived dendritic cells by lithium chloride. *J Cell Physiol*. 2011; 226(2):424–33. Epub 2010/07/31. doi: [10.1002/jcp.22348](https://doi.org/10.1002/jcp.22348) PMID: [20672290](https://pubmed.ncbi.nlm.nih.gov/20672290/).
36. Litherland GJ, Hui W, Elias MS, Wilkinson DJ, Watson S, Huesa C, et al. Glycogen synthase kinase 3 inhibition stimulates human cartilage destruction and exacerbates murine osteoarthritis. *Arthritis Rheumatol*. 2014; 66(8):2175–87. Epub 2014/04/24. doi: [10.1002/art.38681](https://doi.org/10.1002/art.38681) PMID: [24757033](https://pubmed.ncbi.nlm.nih.gov/24757033/).
37. Alvarez-Garcia O, Garcia-Lopez E, Loredo V, Gil-Pena H, Mejia-Gaviria N, Rodriguez-Suarez J, et al. Growth hormone improves growth retardation induced by rapamycin without blocking its antiproliferative and antiangiogenic effects on rat growth plate. *PLoS One*. 2012; 7(4):e34788. Epub 2012/04/12. doi: [10.1371/journal.pone.0034788](https://doi.org/10.1371/journal.pone.0034788) PMID: [22493717](https://pubmed.ncbi.nlm.nih.gov/22493717/); PubMed Central PMCID: [PMC3321024](https://pubmed.ncbi.nlm.nih.gov/PMC3321024/).

38. Aigner T, Hemmel M, Neureiter D, Gebhard PM, Zeiler G, Kirchner T, et al. Apoptotic cell death is not a widespread phenomenon in normal aging and osteoarthritis human articular knee cartilage: a study of proliferation, programmed cell death (apoptosis), and viability of chondrocytes in normal and osteoarthritic human knee cartilage. *Arthritis and Rheumatism*. 2001; 44(6):1304–12. Epub 2001/06/16. doi: [10.1002/1529-0131\(200106\)44:6<1304::AID-ART222>3.0.CO;2-T](https://doi.org/10.1002/1529-0131(200106)44:6<1304::AID-ART222>3.0.CO;2-T) PMID: [11407689](https://pubmed.ncbi.nlm.nih.gov/11407689/).
39. Price JS, Waters JG, Darrah C, Pennington C, Edwards DR, Donell ST, et al. The role of chondrocyte senescence in osteoarthritis. *Aging Cell*. 2002; 1(1):57–65. Epub 2003/07/29. PMID: [12882354](https://pubmed.ncbi.nlm.nih.gov/12882354/).
40. Gallo LI, Lagadari M, Piwien-Pilipuk G, Galigniana MD. The 90-kDa heat-shock protein (Hsp90)-binding immunophilin FKBP51 is a mitochondrial protein that translocates to the nucleus to protect cells against oxidative stress. *J Biol Chem*. 2011; 286(34):30152–60. Epub 2011/07/07. doi: [10.1074/jbc.M111.256610](https://doi.org/10.1074/jbc.M111.256610) M111.256610 [pii]. PMID: [21730050](https://pubmed.ncbi.nlm.nih.gov/21730050/); PubMed Central PMCID: PMC3191054.
41. Tsuchimochi K, Otero M, Dragomir CL, Plumb DA, Zerbini LF, Libermann TA, et al. GADD45beta enhances Col10a1 transcription via the MTK1/MKK3/6/p38 axis and activation of C/EBPbeta-TAD4 in terminally differentiating chondrocytes. *J Biol Chem*. 2010; 285(11):8395–407. Epub 2010/01/06. doi: [10.1074/jbc.M109.038638](https://doi.org/10.1074/jbc.M109.038638) M109.038638 [pii]. PMID: [20048163](https://pubmed.ncbi.nlm.nih.gov/20048163/); PubMed Central PMCID: PMC2832989.
42. Ijiri K, Zerbini LF, Peng HB, Correa RG, Lu BF, Walsh N, et al. A novel role for GADD45 beta as a mediator of MMP-13 gene expression during chondrocyte terminal differentiation. *Journal of Biological Chemistry*. 2005; 280(46):38544–55. doi: [10.1074/jbc.M504202200](https://doi.org/10.1074/jbc.M504202200) PMID: [ISI:000233239800053](https://pubmed.ncbi.nlm.nih.gov/151000233239800053/).
43. Bhattacharjee RN, Park KS, Uematsu S, Okada K, Hoshino K, Takeda K, et al. Escherichia coli verotoxin 1 mediates apoptosis in human HCT116 colon cancer cells by inducing overexpression of the GADD family of genes and S phase arrest. *FEBS Lett*. 2005; 579(29):6604–10. Epub 2005/11/22. doi: [10.1016/j.febslet.2005.10.053](https://doi.org/10.1016/j.febslet.2005.10.053) PMID: [16297916](https://pubmed.ncbi.nlm.nih.gov/16297916/).
44. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. *Proc Natl Acad Sci U S A*. 1997; 94(2):514–9. Epub 1997/01/21. PMID: [9012815](https://pubmed.ncbi.nlm.nih.gov/9012815/); PubMed Central PMCID: PMC19544.
45. Rabie AB, Tang GH, Hagg U. Cbfa1 couples chondrocytes maturation and endochondral ossification in rat mandibular condylar cartilage. *Arch Oral Biol*. 2004; 49(2):109–18. Epub 2003/12/25. doi: [S0003996903002358](https://pubmed.ncbi.nlm.nih.gov/S0003996903002358) [pii]. PMID: [14693204](https://pubmed.ncbi.nlm.nih.gov/14693204/).
46. Nakanishi A, Wada Y, Kitagishi Y, Matsuda S. Link between PI3K/AKT/PTEN Pathway and NOX Protein in Diseases. *Aging Dis*. 2014; 5(3):203–11. Epub 2014/06/06. doi: [10.14336/AD.2014.0500203](https://doi.org/10.14336/AD.2014.0500203) ad-5-3-203 [pii]. PMID: [24900943](https://pubmed.ncbi.nlm.nih.gov/24900943/); PubMed Central PMCID: PMC4037312.
47. Philipot D, Guerit D, Platano D, Chuchana P, Olivetto E, Espinoza F, et al. p16INK4a and its regulator miR-24 link senescence and chondrocyte terminal differentiation-associated matrix remodelling in osteoarthritis. *Arthritis Res Ther*. 2014; 16(1):R58. Epub 2014/02/28. doi: [ar4494](https://doi.org/10.1186/ar4494) [pii] doi: [10.1186/ar4494](https://doi.org/10.1186/ar4494) PMID: [24572376](https://pubmed.ncbi.nlm.nih.gov/24572376/).
48. Ryu JH, Kim SJ, Kim SH, Oh CD, Hwang SG, Chun CH, et al. Regulation of the chondrocyte phenotype by beta-catenin. *Development*. 2002; 129(23):5541–50. Epub 2002/10/31. PMID: [12403723](https://pubmed.ncbi.nlm.nih.gov/12403723/).
49. Hui W, Litherland GJ, Jefferson M, Barter MJ, Elias MS, Cawston TE, et al. Lithium protects cartilage from cytokine-mediated degradation by reducing collagen-degrading MMP production via inhibition of the P38 mitogen-activated protein kinase pathway. *Rheumatology (Oxford)*. 2010; 49(11):2043–53. Epub 2010/07/17. doi: [10.1093/rheumatology/keq217](https://doi.org/10.1093/rheumatology/keq217) keq217 [pii]. PMID: [20634235](https://pubmed.ncbi.nlm.nih.gov/20634235/).
50. Gavrilov B, Vezhenkova I, Firsanov D, Solovjeva L, Svetlova M, Mikhailov V, et al. Slow elimination of phosphorylated histone gamma-H2AX from DNA of terminally differentiated mouse heart cells in situ. *Biochem Biophys Res Commun*. 2006; 347(4):1048–52. Epub 2006/07/22. doi: [S0006-291X\(06\)01521-X](https://doi.org/S0006-291X(06)01521-X) [pii] doi: [10.1016/j.bbrc.2006.07.005](https://doi.org/10.1016/j.bbrc.2006.07.005) PMID: [16857171](https://pubmed.ncbi.nlm.nih.gov/16857171/).
51. Svetlova MP, Solovjeva LV, Tomilin NV. Mechanism of elimination of phosphorylated histone H2AX from chromatin after repair of DNA double-strand breaks. *Mutat Res*. 2010; 685(1–2):54–60. Epub 2009/08/18. doi: [10.1016/j.mrfmmm.2009.08.001](https://doi.org/10.1016/j.mrfmmm.2009.08.001) S0027-5107(09)00247-4 [pii]. PMID: [19682466](https://pubmed.ncbi.nlm.nih.gov/19682466/).
52. Shane Anderson A, Loeser RF. Why is osteoarthritis an age-related disease? *Best Pract Res Clin Rheumatol*. 2010; 24(1):15–26. Epub 2010/02/05. doi: [S1521-6942\(09\)00084-9](https://doi.org/S1521-6942(09)00084-9) [pii] doi: [10.1016/j.berh.2009.08.006](https://doi.org/10.1016/j.berh.2009.08.006) PMID: [20129196](https://pubmed.ncbi.nlm.nih.gov/20129196/); PubMed Central PMCID: PMC2818253.
53. Loeser RF. Aging and osteoarthritis. *Curr Opin Rheumatol*. 2011; 23(5):492–6. Epub 2011/06/29. doi: [10.1097/BOR.0b013e3283494005](https://doi.org/10.1097/BOR.0b013e3283494005) PMID: [21709557](https://pubmed.ncbi.nlm.nih.gov/21709557/); PubMed Central PMCID: PMC3377970.
54. Zhou HW, Lou SQ, Zhang K. Recovery of function in osteoarthritic chondrocytes induced by p16INK4a-specific siRNA in vitro. *Rheumatology (Oxford)*. 2004; 43(5):555–68. Epub 2004/03/18. doi: [10.1093/rheumatology/keh127](https://doi.org/10.1093/rheumatology/keh127) keh127 [pii]. PMID: [15026580](https://pubmed.ncbi.nlm.nih.gov/15026580/).
55. Dai SM, Shan ZZ, Nakamura H, Masuko-Hongo K, Kato T, Nishioka K, et al. Catabolic stress induces features of chondrocyte senescence through overexpression of caveolin 1: possible involvement of caveolin 1-induced down-regulation of articular chondrocytes in the pathogenesis of osteoarthritis.

Arthritis and Rheumatism. 2006; 54(3):818–31. Epub 2006/03/02. doi: [10.1002/art.21639](https://doi.org/10.1002/art.21639) PMID: [16508959](https://pubmed.ncbi.nlm.nih.gov/16508959/).

56. Stewart MC, Farnum CE, MacLeod JN. Expression of p21CIP1/WAF1 in chondrocytes. *Calcif Tissue Int.* 1997; 61(3):199–204. Epub 1997/09/01. PMID: [9262510](https://pubmed.ncbi.nlm.nih.gov/9262510/).